|
1
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: the impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Parkin DM: Global cancer statistics in the
year 2000. Lancet Oncol. 2:533–543. 2001.PubMed/NCBI
|
|
3
|
Li M, Zhang Q, Fu P, et al: Pemetrexed
plus platinum as the first-line treatment option for advanced
non-small cell lung cancer: a meta-analysis of randomized
controlled trials. PLoS One. 7:e372292012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Smith RA, Brooks D, Cokkinides V, et al:
Cancer screening in the United States, 2013: a review of current
American Cancer Society guidelines, current issues in cancer
screening, and new guidance on cervical cancer screening and lung
cancer screening. CA Cancer J Clin. 63:88–105. 2013. View Article : Google Scholar
|
|
5
|
Goldstraw P, Ball D, Jett JR, et al:
Non-small-cell lung cancer. Lancet. 378:1727–1740. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rami-Porta R and Goldstraw P: Strength and
weakness of the new TNM classification for lung cancer. Eur Respir
J. 36:237–239. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
van Kouwenhove M, Kedde M and Agami R:
MicroRNA regulation by RNA-binding proteins and its implications
for cancer. Nat Rev Cancer. 11:644–656. 2011.PubMed/NCBI
|
|
9
|
Chen X, Ba Y, Ma L, et al:
Characterization of microRNAs in serum: a novel class of biomarkers
for diagnosis of cancer and other diseases. Cell Res. 18:997–1006.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kong YW, Ferland-McCollough D, Jackson TJ
and Bushell M: microRNAs in cancer management. Lancet Oncol.
13:e249–e258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lu J, Getz G, Miska EA, et al: MicroRNA
expression profiles classify human cancers. Nature. 435:834–838.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mitchell PS, Parkin RK, Kroh EM, et al:
Circulating microRNAs as stable blood-based markers for cancer
detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Voortman J, Goto A, Mendiboure J, et al:
MicroRNA expression and clinical outcomes in patients treated with
adjuvant chemotherapy after complete resection of non-small cell
lung carcinoma. Cancer Res. 70:8288–8298. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hu Z, Chen X, Zhao Y, et al: Serum
microRNA signatures identified in a genome-wide serum microRNA
expression profiling predict survival of non-small-cell lung
cancer. J Clin Oncol. 28:1721–1726. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Markou A, Sourvinou I, Vorkas PA, et al:
Clinical evaluation of microRNA expression profiling in non small
cell lung cancer. Lung Cancer. 81:388–396. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vinci S, Gelmini S, Pratesi N, et al:
Genetic variants in miR-146a, miR-149,
miR-196a2, miR-499 and their influence on relative
expression in lung cancers. Clin Chem Lab Med. 49:2073–2080.
2011.
|
|
17
|
Kroh EM, Parkin RK, Mitchell PS and Tewari
M: Analysis of circulating microRNA biomarkers in plasma and serum
using quantitative reverse transcription-PCR (qRT-PCR). Methods.
50:298–301. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods.
25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Peltier HJ and Latham GJ: Normalization of
microRNA expression levels in quantitative RT-PCR assays:
identification of suitable reference RNA targets in normal and
cancerous human solid tissues. RNA. 14:844–852. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ruopp MD, Perkins NJ, Whitcomb BW and
Schisterman EF: Youden Index and optimal cut-point estimated from
observations affected by a lower limit of detection. Biom J.
50:419–430. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yanaihara N, Caplen N, Bowman E, et al:
Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu SL, Chen HY, Chang GC, et al: MicroRNA
signature predicts survival and relapse in lung cancer. Cancer
Cell. 13:48–57. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takamizawa J, Konishi H, Yanagisawa K, et
al: Reduced expression of the let-7 microRNAs in human lung
cancers in association with shortened postoperative survival.
Cancer Res. 64:3753–3756. 2004.PubMed/NCBI
|
|
24
|
Lawrie CH, Gal S, Dunlop HM, et al:
Detection of elevated levels of tumour-associated microRNAs in
serum of patients with diffuse large B-cell lymphoma. Br J
Haematol. 141:672–675. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Boeri M, Verri C, Conte D, et al: MicroRNA
signatures in tissues and plasma predict development and prognosis
of computed tomography detected lung cancer. Proc Natl Acad Sci
USA. 108:3713–3718. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang GK, Zhu JQ, Zhang JT, et al:
Circulating microRNA: a novel potential biomarker for early
diagnosis of acute myocardial infarction in humans. Eur Heart J.
31:659–666. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Donaldson A, Natanek SA, Lewis A, et al:
Increased skeletal muscle-specific microRNA in the blood of
patients with COPD. Thorax. 68:1140–1149. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
National Lung Screening Trial Research
Team. Aberle DR, Adams AM, Berg CD, et al: Reduced lung-cancer
mortality with low-dose computed tomographic screening. N Engl J
Med. 365:395–409. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Infante M, Cavuto S, Lutman FR, et al: A
randomized study of lung cancer screening with spiral computed
tomography: three-year results from the DANTE trial. Am J Respir
Crit Care Med. 180:445–453. 2009.PubMed/NCBI
|
|
30
|
Shen J, Liu Z, Todd NW, et al: Diagnosis
of lung cancer in individuals with solitary pulmonary nodules by
plasma microRNA biomarkers. BMC Cancer. 11:3742011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cazzoli R, Buttitta F, Di Nicola M, et al:
microRNAs derived from circulating exosomes as noninvasive
biomarkers for screening and diagnosing lung cancer. J Thorac
Oncol. 8:1156–1162. 2013. View Article : Google Scholar : PubMed/NCBI
|
